Mereo BioPharma Group plc
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $56.3M
- Price
- $0.3528
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.77%
- Volume
- 1.1M
About
Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment. Another cancer compound, Navicixizumab (OMP-305B83), has already concluded its Phase 1b clinical studies for patients battling late-stage ovarian cancer. Beyond cancer, Mereo is advancing several other promising candidates. These include Acumapimod (BCT-197), a p38 MAP kinase inhibitor, which is currently in Phase II clinical trials for addressing acute exacerbations of chronic obstructive pulmonary disease. Additionally, Leflutrozole (BGS-649), an oral aromatase inhibitor, is being developed to manage hypogonadotropic hypogonadism. Within its rare disease portfolio, Mereo features Setrusumab (BPS-804), a novel antibody designed to treat osteogenesis imperfecta, and Alvelestat (MPH-966), an oral small molecule in Phase II clinical trials for Alpha-1 antitrypsin deficiency. To bolster its research, Mereo BioPharma collaborates with The University of Texas MD Anderson Cancer Center, focusing on the evaluation of its anti-TIGIT therapeutic antibody candidate, etigilimab.
Quick stats
Shares outstanding159.7M
Computed float135.4M
Float / shares84.8%
Cash runway (months)11.7
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001719714
AI Summary
AI-generated1/6
majormixedearnings
Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights
Mereo reported a Q2 net loss of $7.0 million, narrowed from $14.6 million in the prior year, with cash and cash equivalents of $30.1 million now expected to fund operations into late 2027.
The company announced an option and license agreement with Sentynl Therapeutics for alvelestat, potentially generating $40 million in upfront payments and up to $435 million in milestones if the option is exercised.
However, Phase 3 studies for setrusumab missed statistical significance on primary fracture reduction endpoints, though they demonstrated significant improvements in bone mineral density and vertebral fractures.
Red flags
- Setrusumab Phase 3 studies (Orbit and Cosmic) did not achieve statistical significance against primary endpoints
- Cash balance of $30.1M remains low, requiring efficient execution or deal monetization